We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-0.32%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$970M
AUM Growth
-$417M
Cap. Flow
-$194M
Cap. Flow %
-20.04%
Top 10 Hldgs %
49.08%
Holding
83
New
26
Increased
6
Reduced
23
Closed
17

Top Buys

Rank Stock Value
1
RPTX
Repare Therapeutics
RPTX
+$39.6M
2
VTYX
Ventyx Biosciences
VTYX
+$34.6M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$23.2M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$21.3M
5
ALGS icon
Aligos Therapeutics
ALGS
+$16.8M

Top Sells

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$62.9M
2
PMVP icon
PMV Pharmaceuticals
PMVP
+$41.7M
3
NKTX icon
Nkarta
NKTX
+$35.5M
4
CMPS
Compass Pathways
CMPS
+$35M
5
BCYC
Bicycle Therapeutics
BCYC
+$33.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STTK icon
76
Shattuck Labs
STTK
$651M
– –
-200,000
Closed -$4.08M
SYBX
77
DELISTED
Synlogic
SYBX
– –
-100,000
Closed -$4.58M
TIL icon
78
Instil Bio
TIL
$49.4M
– –
-63,855
Closed -$22.8M
VRDN icon
79
Viridian Therapeutics
VRDN
$2.15B
– –
-1,500,000
Closed -$24.7M
DCPH
80
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-1,850,000
Closed -$62.9M
KNTE
81
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
– –
-94,345
Closed -$2.17M
BCEL
82
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
– –
-1,175,000
Closed -$7.32M
ARNA
83
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-510,000
Closed -$30.4M
1 2 3
4

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q4 2021 Portfolio in Review

As of Q4 2021, Logos Global Management held 83 positions worth $970M, down 30% from $1.39B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Logos Global Management withdrew a net $194M in Q4 2021, closing 17 positions and reducing 23 holdings. Its most notable exit was Deciphera Pharmaceuticals, Inc. Common Stock, an estimated $62.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Logos Global Management opened a new position in Ventyx Biosciences worth $36.2M.

  • Logos Global Management's largest Q4 2021 buy was Ventyx Biosciences: 1,824,280 shares worth $36.2M.
  • Logos Global Management added most to Repare Therapeutics in Q4 2021, an estimated $39.6M increase.
  • Logos Global Management's biggest Q4 2021 reduction was Compass Pathways, cutting an estimated $35M.
  • Logos Global Management fully exited Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2021, selling an estimated $62.9M.
  • Logos Global Management's ten largest holdings make up 49% of its $970M portfolio in Q4 2021.
  • Logos Global Management opened 26 new positions and closed 17 in Q4 2021.
  • Logos Global Management's portfolio value fell 30% quarter-over-quarter to $970M.

Based on Logos Global Management's 13F filing for Q4 2021, filed 14 Feb 2022.